Kalbe Farma Plans To Consistently Distribute Dividends Of Up To 55 Percent

JAKARTA PT Kalbe Farma Tbk (KLBF) plans to consistently distribute dividends with a dividend payout ratio of 45 percent to 55 percent of the total net profit in the 2023 financial year.

KLBF Chief Financial Officer Kartika Setiabudy said that regarding dividend distribution, the company has a policy to always distribute dividends regularly every year with a ratio range of 45 percent to 55 percent of profit.

"We will polycy distribute dividends of 45-55 percent of the total net profit, this commitment we also hold in the future so that we can provide good results or returns to shareholders," he said in a public expose live, Tuesday, November 28.

This year, KLBF has distributed dividends with a total value of IDR 1.76 trillion or equivalent to IDR 38 per share for the 2022 financial year. The dividend payment will be made on May 31, 2023.

Meanwhile, in terms of the payment ratio or dividend payout ratio (DPR), the total dividend distributed is higher when compared to the 2021 financial year where for 2021 it is 52 percent while in 2022 it will reach 52.5 percent.

In terms of performance, based on financial reports as of the end of September 2023, KLBF recorded net sales of IDR 22.561 billion in the first nine months of 2023, an increase of 6.5 percent compared to the first nine months of 2022.

Meanwhile, in terms of growth and contribution per Division, the Company's Recipe Drug Division posted an increase in sales by 31.4 percent to Rp5,791 billion from Rp4,406 billion in the first nine months of 2022, and contributed 25.7 percent of the Company's total net sales.

Meanwhile, the Distribution & Logistics Division achieved an increase in net sales by 3.2 percent to Rp8,006 billion, from Rp7,758 billion in the same period last year, and contributed 35.5 percent to the Company's total net sales.

The Nutrition Division posted net sales of IDR 5,895 billion in the first nine months of 2023, growing by 2.5 percent from the achievement in the same period the previous year and contributing 26.1 percent of Kalbe's total net sales in the first nine months of 2023.

On the other hand, in the first nine months of 2023, there was a decrease in revenue from the Health Products Division by 12.1 percent compared to the first nine months of 2022 to Rp2,869 billion with a contribution of 12.7 percent to the total net sales of KLBF in the first nine months of 2023.

Meanwhile, operating profit reached IDR 2,715 billion in the first nine months of 2023, with a operating profit to sales ratio of 12.0 percent. Profit per share reached IDR 44.39 in the first nine months of 2023, down 16.9 percent compared to the same period the previous year.